# Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

> **NCT03919539** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Drug Resistance to Famitinib and Camrelizumab
- Biomarkers for Efficacy and Toxicity

## Interventions

- **DIAGNOSTIC_TEST:** 5hmc testing

## Key facts

- **NCT ID:** NCT03919539
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03919539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03919539, "Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT03919539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*